Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207530 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT02207530 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 112 participants.
The verdict
NCT02207530, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR
Interventions
- DRUG MEDI4736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2014-10-23 |
| Est. Completion | 2020-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207530
The ClinicalTrials.gov registry entry for NCT02207530 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI4736 is the first listed.
NCT02207530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207530 about?
NCT02207530 is a clinical study titled "Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR
What is the current status of trial NCT02207530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2014-10-23. Estimated completion is 2020-07-06.
What interventions are being tested in trial NCT02207530?
The interventions under investigation include: MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT02207530?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.